New England Journal of Medicine · 2016 · 1.8K citations · 19 references
MedicineImmunologyOncologyImmunotherapyNeuro-oncologyNeuroimmunologyBrain TumorsCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyGlioblastomaImmunotherapy For Brain TumorsTumor-associated AntigensCar T Cell TrialsChimeric Antigen Receptor T-cell Therapy ToxicityDurable Clinical ResponseGlioblastoma Clinical TrialsGlioblastoma ImmunologyGlioblastoma ImmunotherapyGlioblastoma TrialsImmunotherapy Trials
A patient with recurrent multifocal glioblastoma received IL13Rα2‑targeted CAR‑T cells, administered in multiple infusions over 220 days via the resected tumor cavity and ventricular system. The treatment produced regression of all intracranial and spinal tumors, sustained for 7.5 months, without grade 3 or higher toxicity, and was accompanied by increased cerebrospinal fluid cytokines and immune cells. The study was funded by Gateway for Cancer Research and others and registered under ClinicalTrials.gov NCT02208362.
A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362 . ).
19